Karl Haslam

530 total citations
30 papers, 267 citations indexed

About

Karl Haslam is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Karl Haslam has authored 30 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 22 papers in Hematology and 14 papers in Molecular Biology. Recurrent topics in Karl Haslam's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers), Chronic Myeloid Leukemia Treatments (14 papers) and Acute Myeloid Leukemia Research (12 papers). Karl Haslam is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers), Chronic Myeloid Leukemia Treatments (14 papers) and Acute Myeloid Leukemia Research (12 papers). Karl Haslam collaborates with scholars based in Ireland, United Kingdom and United States. Karl Haslam's co-authors include Stephen E. Langabeer, Eibhlin Conneally, Yuntao Xie, Armando Bartolazzi, Bertha Brodin, Olle Larsson, Nils Mandahl, Alessandra Gasbarri, Björn Skytting and Ke Yang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Gene.

In The Last Decade

Karl Haslam

26 papers receiving 263 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karl Haslam Ireland 8 142 130 101 87 80 30 267
Susanne Isfort Germany 10 202 1.4× 164 1.3× 149 1.5× 65 0.7× 28 0.3× 40 346
Susanna Akiki Qatar 9 141 1.0× 219 1.7× 167 1.7× 58 0.7× 17 0.2× 32 347
Borhane Slama France 7 132 0.9× 147 1.1× 91 0.9× 51 0.6× 9 0.1× 29 240
Stacey Kalambakas United States 9 136 1.0× 69 0.5× 163 1.6× 18 0.2× 40 0.5× 17 295
Sabrina Cordua Denmark 8 235 1.7× 187 1.4× 102 1.0× 88 1.0× 11 0.1× 15 304
Alexandre Guy France 9 166 1.2× 143 1.1× 113 1.1× 88 1.0× 15 0.2× 27 287
Kaddour Chabane France 10 126 0.9× 128 1.0× 86 0.9× 52 0.6× 7 0.1× 17 242
Andrea Viqueira Spain 10 151 1.1× 277 2.1× 72 0.7× 77 0.9× 11 0.1× 59 355
Jacob Grinfeld United Kingdom 11 277 2.0× 228 1.8× 177 1.8× 112 1.3× 15 0.2× 19 365
Ronan Chaligné France 8 324 2.3× 296 2.3× 223 2.2× 106 1.2× 9 0.1× 12 439

Countries citing papers authored by Karl Haslam

Since Specialization
Citations

This map shows the geographic impact of Karl Haslam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl Haslam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl Haslam more than expected).

Fields of papers citing papers by Karl Haslam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karl Haslam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl Haslam. The network helps show where Karl Haslam may publish in the future.

Co-authorship network of co-authors of Karl Haslam

This figure shows the co-authorship network connecting the top 25 collaborators of Karl Haslam. A scholar is included among the top collaborators of Karl Haslam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karl Haslam. Karl Haslam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Frawley, Thomas F., Cathal Ó’Brien, Eibhlin Conneally, et al.. (2018). Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2 , CALR , and MPL in Myeloproliferative Neoplasms. Genetic Testing and Molecular Biomarkers. 22(2). 98–103. 6 indexed citations
4.
Crampe, Mireille, Karl Haslam, Emma M. Groarke, et al.. (2017). Chronic Myeloid Leukemia with an e6a2BCR-ABL1Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring. SHILAP Revista de lepidopterología. 2017. 1–5. 2 indexed citations
5.
Langabeer, Stephen E., et al.. (2017). Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. Clinical & Translational Oncology. 20(3). 420–423. 17 indexed citations
6.
Haslam, Karl & Stephen E. Langabeer. (2017). Who to screen for calreticulin mutations? An audit of real-life practice and review of current evidence. European Journal of Internal Medicine. 40. e22–e23. 3 indexed citations
7.
O’Connor, Louise, Janusz Krawczyk, Margaret Murray, et al.. (2017). A novel molecular assay using hybridisation probes and melt curve analysis for CALR exon 9 mutation detection in myeloproliferative neoplasms. Journal of Clinical Pathology. 70(8). 662–668. 1 indexed citations
8.
Haslam, Karl & Stephen E. Langabeer. (2016). Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches. BioMed Research International. 2016. 1–6. 8 indexed citations
9.
Crampe, Mireille, et al.. (2016). Characterization of a novel variant BCR–ABL1 fusion transcript in a patient with chronic myeloid leukemia. Hematology/Oncology and Stem Cell Therapy. 10(2). 85–88. 4 indexed citations
10.
Haslam, Karl, Eibhlin Conneally, Catherine Flynn, et al.. (2016). CALR mutation profile in Irish patients with myeloproliferative neoplasms. Hematology/Oncology and Stem Cell Therapy. 9(3). 112–115. 2 indexed citations
11.
Haslam, Karl, Mark Catherwood, Edwina Dobbin, et al.. (2016). Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia. Molecular Diagnosis & Therapy. 20(5). 457–461. 6 indexed citations
12.
McCarron, Sarah L., et al.. (2015). Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR–ABL1 fusion. Medical Oncology. 32(2). 452–452. 9 indexed citations
13.
Haslam, Karl & Stephen E. Langabeer. (2014). Considerations and Recommendations for a New Molecular Diagnostic Algorithm for the Myeloproliferative Neoplasms. Genetic Testing and Molecular Biomarkers. 18(11). 749–753. 1 indexed citations
14.
Langabeer, Stephen E., Karl Haslam, Melanie J. Percy, et al.. (2014). Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations. Familial Cancer. 13(4). 659–663. 2 indexed citations
15.
Langabeer, Stephen E., Karl Haslam, & Eibhlin Conneally. (2014). Monitoring Residual Disease in the Ph-Negative Myeloproliferative Neoplasms Post-Allogeneic Stem Cell Transplantation: More Mutations and More Methodologies. Frontiers in Oncology. 4. 212–212. 3 indexed citations
16.
Langabeer, Stephen E., Karl Haslam, & Corrina McMahon. (2014). Distinct driver mutation profiles of childhood and adolescent essential thrombocythemia. Pediatric Blood & Cancer. 62(1). 175–176.
17.
Langabeer, Stephen E., Karl Haslam, & Corrina McMahon. (2014). CALR mutations are rare in childhood essential thrombocythemia. Pediatric Blood & Cancer. 61(8). 1523–1523. 5 indexed citations
18.
Langabeer, Stephen E., et al.. (2011). Acute Lymphoblastic Leukaemia with an e1a3 <i>BCR-ABL1</i> Fusion. Acta Haematologica. 126(4). 214–215. 7 indexed citations
19.
Haslam, Karl, Nicholas Chadwick, Paul Browne, et al.. (2010). Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia. Irish Journal of Medical Science (1971 -). 179(4). 507–510. 4 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susanne Isfort Breakdown of academic impact, for papers by Susanna Akiki Breakdown of academic impact, for papers by Borhane Slama Breakdown of academic impact, for papers by Stacey Kalambakas Breakdown of academic impact, for papers by Sabrina Cordua Breakdown of academic impact, for papers by Alexandre Guy Breakdown of academic impact, for papers by Kaddour Chabane Breakdown of academic impact, for papers by Andrea Viqueira Breakdown of academic impact, for papers by Jacob Grinfeld Breakdown of academic impact, for papers by Ronan Chaligné
Rankless by CCL
2026